Shlevin Harold H. Form 4 August 29, 2012

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL

Number: 3235-0287

Expires: 2005
Estimated average

0.5

burden hours per response...

5. Relationship of Reporting Person(s) to

6. Individual or Joint/Group Filing(Check

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

Shlevin Harold H.

GALECTIN THERAPEUTICS INC (Check all applicable) [GALT] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X\_ Officer (give title Other (specify (Month/Day/Year) below) **GALECTIN THERAPEUTICS** 08/27/2012 Chief Operating Officer

2. Issuer Name and Ticker or Trading

INC., 7 WELLS AVENUE, SUITE 34

(State)

1. Name and Address of Reporting Person \*

(Street) 4. If Amendment, Date Original

(Zip)

Symbol

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Issuer

NEWTON, MA 02459

(City)

1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of Form: Direct Indirect Security (Month/Day/Year) Execution Date, if TransactionAcquired (A) or Securities (Instr. 3) Code Disposed of (D) Beneficially (D) or Indirect Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Ownership Following (Instr. 4) (Instr. 4) Reported

(A) Transaction(s)
Or (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: Shlevin Harold H. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A Disposed of (Instr. 3, 4, a 5)	A) or (D)	6. Date Exercisab Expiration Date (Month/Day/Year		7. Title and A Underlying S (Instr. 3 and 4	Securitie
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock Options	\$ 2.32	08/27/2012		A	250,000		08/27/2012(1)	08/27/2022	Common Stock	250,0

### **Reporting Owners**

Relationships Reporting Owner Name / Address 10% Owner Officer Other Director

Shlevin Harold H. GALECTIN THERAPEUTICS INC. 7 WELLS AVENUE, SUITE 34 NEWTON, MA 02459

**Chief Operating Officer** 

## **Signatures**

/s/ Harold H. 08/29/2012 Shlevin

\*\*Signature of Date Reporting Person

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Stock options vest as follows: 50,000 shares vested on August 27, 2012, 50,000 shares will vest on December 31, 2012, 75,000 shares **(1)** will vest on December 31, 2013, and 75,000 shares will vest on December 31, 2014.

#### **Remarks:**

On August 27, 2012, the Issuer appointed the Reporting Person as the Issuer's Chief Operating Officer effective October 1, 20 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2